A Phase II Clinical Trial to Investigate Efficacy and Safety of Apatinib as a Single Agent in RET-fusion Gene Positive Non-small Cell Lung Cancer Who Failed to Previous Treatment.
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Sep 2015 New trial record